Angela Koehler
Fondateur chez 76bio, Inc.
Profil
Angela Koehler is the founder of Ligon Discovery, Inc. (founded in 2007) and Kronos Bio, Inc. (founded in 2017).
Dr. Koehler holds a doctorate degree from Harvard University.
Dr. Koehler is also the founder of 76Bio, Inc.
Postes actifs de Angela Koehler
| Sociétés | Poste | Début |
|---|---|---|
76bio, Inc.
 76bio, Inc. Pharmaceuticals: MajorHealth Technology 76Bio, Inc. is a private company that aims to develop transformational therapies for patients with life-threatening diseases. The company is based in New York, NY. The company focuses on pioneering the next generation of degradation by design. 76Bio was founded by Joshua A. Kazam, David M. Tanen, Marius Pop, Christopher Wilfong, Ben Stone, Angela Koehler, Arie S. Belldegrun, and K. Dane Wittrup. Christopher Wilfong has been the CEO since incorporation. | Fondateur | - |
Anciens postes connus de Angela Koehler
| Sociétés | Poste | Fin |
|---|---|---|
| KRONOS BIO, INC. | Fondateur | - |
Ligon Discovery, Inc.
 Ligon Discovery, Inc. Miscellaneous Commercial ServicesCommercial Services Ligon Discovery's primary technology platform, Small-Molecule Microarrays (SMMs), fundamentally transforms drug discovery by bringing the power of microarrays to target screening. SMMs, developed at Harvard University and the Broad Institute, use a proprietary surface chemistry to attach unmodified chemical collections to a solid surface, enabling massively-parallel screening against protein targets of any function. The scale and scope of SMMs permit a paradigmatic change in drug discovery strategy as entire protein families, molecular pathways, and even genome-wide target sets can be screened in parallel to rapidly identify small molecules with optimal characteristics for drug development. Ligon is applying SMM technology to challenging, novel targets aimed at discovery of first-in-class drugs for oncology and other selected diseases. Ligon Discovery's SMM platform is available for drug discovery collaborations. | Fondateur | - |
Formation de Angela Koehler
| Harvard University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| KRONOS BIO, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Ligon Discovery, Inc.
Ligon Discovery, Inc. Miscellaneous Commercial ServicesCommercial Services Ligon Discovery's primary technology platform, Small-Molecule Microarrays (SMMs), fundamentally transforms drug discovery by bringing the power of microarrays to target screening. SMMs, developed at Harvard University and the Broad Institute, use a proprietary surface chemistry to attach unmodified chemical collections to a solid surface, enabling massively-parallel screening against protein targets of any function. The scale and scope of SMMs permit a paradigmatic change in drug discovery strategy as entire protein families, molecular pathways, and even genome-wide target sets can be screened in parallel to rapidly identify small molecules with optimal characteristics for drug development. Ligon is applying SMM technology to challenging, novel targets aimed at discovery of first-in-class drugs for oncology and other selected diseases. Ligon Discovery's SMM platform is available for drug discovery collaborations. | Commercial Services |
76bio, Inc.
76bio, Inc. Pharmaceuticals: MajorHealth Technology 76Bio, Inc. is a private company that aims to develop transformational therapies for patients with life-threatening diseases. The company is based in New York, NY. The company focuses on pioneering the next generation of degradation by design. 76Bio was founded by Joshua A. Kazam, David M. Tanen, Marius Pop, Christopher Wilfong, Ben Stone, Angela Koehler, Arie S. Belldegrun, and K. Dane Wittrup. Christopher Wilfong has been the CEO since incorporation. | Health Technology |